Trial Profile
A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab; Carboplatin; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel; Pemetrexed
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; HER2 negative breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Genentech
- 06 Oct 2020 Status changed from active, no longer recruiting to completed.
- 28 Jul 2020 Results (data cut off: 23 april 2018; n=20) assessing safety and efficacy of atezolizumab plus bevacizumab in patients with platinum-resistant ovarian cancer cohort published in the Clinical Cancer Research
- 11 Feb 2020 Planned End Date changed from 16 Jan 2020 to 29 Feb 2020.